Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells 50,000 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 50,000 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00. Following the completion of the transaction, the director now directly owns 210,346 shares of the company's stock, valued at $2,334,840.60. The trade was a 19.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Laura Shawver also recently made the following trade(s):

• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.56, for a total transaction of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.75, for a total value of $203,115.00.

ARS Pharmaceuticals Trading Up 2.3 %

NASDAQ:SPRY traded up $0.26 on Tuesday, reaching $11.34. The stock had a trading volume of 922,422 shares, compared to its average volume of 1,272,206. ARS Pharmaceuticals, Inc. has a 12-month low of $5.62 and a 12-month high of $18.51. The company has a 50-day moving average of $13.31 and a 200 day moving average of $12.66. The stock has a market cap of $1.10 billion, a P/E ratio of -22.24 and a beta of 0.96.

Analysts Set New Price Targets

A number of brokerages have issued reports on SPRY. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Leerink Partners increased their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Friday, September 20th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $24.00.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC increased its holdings in ARS Pharmaceuticals by 189.7% in the third quarter. Barclays PLC now owns 111,666 shares of the company's stock valued at $1,618,000 after buying an additional 73,127 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of ARS Pharmaceuticals by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company's stock valued at $17,909,000 after acquiring an additional 38,927 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at approximately $250,000. Wellington Management Group LLP raised its position in shares of ARS Pharmaceuticals by 38.9% during the 3rd quarter. Wellington Management Group LLP now owns 162,335 shares of the company's stock valued at $2,354,000 after acquiring an additional 45,452 shares in the last quarter. Finally, Wexford Capital LP bought a new position in ARS Pharmaceuticals during the third quarter worth $3,601,000. Institutional investors own 68.16% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.